-
Further research will be required to understand the pathogenesis of these disorders.
-
This strategy yields potent inhibitors of A-beta aggregation and could lead to therapeutics for Alzheimers disease and other forms of neurodegeneration.
-
LRRK2 may be central to the pathogenesis of several major neurodegenerative disorders associated with Parkinsonism.
-
Natilizumab will become an important option for newly diagnosed MS patients starting treatment, or for patients currently on interferon beta-1a or glatiramer acetate with refractory breakthrough disease.
-
High-risk patients benefit from perioperative beta-blockers when undergoing major noncardiac surgery according to new study.
-
Patients who have had a transient ischemic attack have not only a high short-term chance of ischemic stroke but also a long-term risk of vascular events over 10 years or more.
-
report provides evidence of a drug target polymorphism in epilepsy patients predictive of their maintenance dose of AEDs.
-
A new from of limbic encephalitis is reported, characterized by neuropil antibodies. Patients show an excellent response to immunotherapy or tumor resection.
-
Better understanding of the mechanisms of the IRIS may enable prevention or cure of this severe, sometimes fatal complication of HAART.
-
Neuropathies with IgM monoclonal gammopathy may respond to various chemotherapeutic agents, although the long-term effects are unknown.